论文部分内容阅读
目的观察西妥昔单抗(Cetuximab,C-225)和表阿霉素(Epirubici,EPI)联合应用对人肝癌HepG2细胞体外生长的影响,并初步探讨其作用机制。方法 MTT(噻唑蓝)比色法测定C-225和EPI对肝癌HepG2细胞增殖的影响。结果:MTT结果显示C-225和EPI可明显抑制HepG2细胞增殖,具有剂量依赖性。结论 C-225和EPI具有协同诱导肝癌HepG2细胞凋亡的作用,机制可能与激活细胞内Caspase-3介导的信号转导通路相关。
Objective To investigate the effects of Cetuximab (C-225) combined with Epirubici (EPI) on the growth of HepG2 human hepatoma cells in vitro and its possible mechanism. Methods The effect of C-225 and EPI on the proliferation of hepatocellular carcinoma HepG2 cells was determined by MTT assay. Results: MTT results showed that C-225 and EPI significantly inhibited the proliferation of HepG2 cells in a dose-dependent manner. Conclusion C-225 and EPI can induce the apoptosis of hepatocellular carcinoma HepG2 cells in a cooperative manner. The mechanism may be related to the activation of intracellular Caspase-3-mediated signal transduction pathway.